Report Detail
Global Cholesterol Lowering Biologic Drugs Market Insights, Forecast to 2025
- RnM2375977 |
- 12 June, 2019 |
- Global |
- 112 Pages |
- QYResearch |
- Pharma & Healthcare
The cholesterol lowering biologic drugs offers a new, revolutionary alternative for people fighting with cholesterol with the same old treatments. The old method of treating cholesterol elevated levels includes a change in diet and consuming statin pills to prevent the body from making more bad cholesterol. The new class of PCSK-9 inhibitors is being approved by the FDA which works by helping the liver flush out the bad cholesterol instead of preventing the body from making low-density lipoproteins. The FDA has till now approved only two drugs Praluent and Repatha, both made from living things. The PCSK-9 is a protein which binds to the receptors, those which are responsible for getting the bad cholesterol out of the body.
The cholesterol lowering biologics drug market is expected to boom owing to the number of population with high cholesterol levels, sedentary lifestyle and increasing research developments. According to the Indian Council of Medical Research, at least three-fourth of the country’s population has dyslipidemia, a condition where the individual has abnormal levels of triglycerides or cholesterol. The risk factors are obesity, hypertension poor lifestyle habits and diabetes. Moreover, the demand for biologics is driven by the dramatic shift in production technology and an expansion of targeted diseases.
The global Cholesterol Lowering Biologic Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Cholesterol Lowering Biologic Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Cholesterol Lowering Biologic Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Cholesterol Lowering Biologic Drugs in these regions.
This research report categorizes the global Cholesterol Lowering Biologic Drugs market by top players/brands, region, type and end user. This report also studies the global Cholesterol Lowering Biologic Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Amgen
Regeneron Pharmaceuticals
Alnylam Pharmaceuticals
Market size by Product
For Oral Administration
Injectable Drugs
Market size by End User
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Sales
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Cholesterol Lowering Biologic Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Cholesterol Lowering Biologic Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Cholesterol Lowering Biologic Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Cholesterol Lowering Biologic Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Cholesterol Lowering Biologic Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Cholesterol Lowering Biologic Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Cholesterol Lowering Biologic Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Cholesterol Lowering Biologic Drugs Market Size Growth Rate by Product
- 1.4.2 For Oral Administration
- 1.4.3 Injectable Drugs
- 1.5 Market by End User
- 1.5.1 Global Cholesterol Lowering Biologic Drugs Market Size Growth Rate by End User
- 1.5.2 Hospital Pharmacies
- 1.5.3 Retail Pharmacies
- 1.5.4 Drug Stores
- 1.5.5 Online Sales
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Cholesterol Lowering Biologic Drugs Market Size
- 2.1.1 Global Cholesterol Lowering Biologic Drugs Revenue 2014-2025
- 2.1.2 Global Cholesterol Lowering Biologic Drugs Sales 2014-2025
- 2.2 Cholesterol Lowering Biologic Drugs Growth Rate by Regions
- 2.2.1 Global Cholesterol Lowering Biologic Drugs Sales by Regions
- 2.2.2 Global Cholesterol Lowering Biologic Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Cholesterol Lowering Biologic Drugs Sales by Manufacturers
- 3.1.1 Cholesterol Lowering Biologic Drugs Sales by Manufacturers
- 3.1.2 Cholesterol Lowering Biologic Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Cholesterol Lowering Biologic Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Cholesterol Lowering Biologic Drugs Revenue by Manufacturers
- 3.2.1 Cholesterol Lowering Biologic Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Cholesterol Lowering Biologic Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Cholesterol Lowering Biologic Drugs Price by Manufacturers
- 3.4 Cholesterol Lowering Biologic Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Cholesterol Lowering Biologic Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Cholesterol Lowering Biologic Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Cholesterol Lowering Biologic Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Cholesterol Lowering Biologic Drugs Sales by Product
- 4.2 Global Cholesterol Lowering Biologic Drugs Revenue by Product
- 4.3 Cholesterol Lowering Biologic Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Cholesterol Lowering Biologic Drugs Breakdown Data by End User
6 North America
- 6.1 North America Cholesterol Lowering Biologic Drugs by Countries
- 6.1.1 North America Cholesterol Lowering Biologic Drugs Sales by Countries
- 6.1.2 North America Cholesterol Lowering Biologic Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Cholesterol Lowering Biologic Drugs by Product
- 6.3 North America Cholesterol Lowering Biologic Drugs by End User
7 Europe
- 7.1 Europe Cholesterol Lowering Biologic Drugs by Countries
- 7.1.1 Europe Cholesterol Lowering Biologic Drugs Sales by Countries
- 7.1.2 Europe Cholesterol Lowering Biologic Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Cholesterol Lowering Biologic Drugs by Product
- 7.3 Europe Cholesterol Lowering Biologic Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Cholesterol Lowering Biologic Drugs by Countries
- 8.1.1 Asia Pacific Cholesterol Lowering Biologic Drugs Sales by Countries
- 8.1.2 Asia Pacific Cholesterol Lowering Biologic Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Cholesterol Lowering Biologic Drugs by Product
- 8.3 Asia Pacific Cholesterol Lowering Biologic Drugs by End User
9 Central & South America
- 9.1 Central & South America Cholesterol Lowering Biologic Drugs by Countries
- 9.1.1 Central & South America Cholesterol Lowering Biologic Drugs Sales by Countries
- 9.1.2 Central & South America Cholesterol Lowering Biologic Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Cholesterol Lowering Biologic Drugs by Product
- 9.3 Central & South America Cholesterol Lowering Biologic Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Cholesterol Lowering Biologic Drugs by Countries
- 10.1.1 Middle East and Africa Cholesterol Lowering Biologic Drugs Sales by Countries
- 10.1.2 Middle East and Africa Cholesterol Lowering Biologic Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Cholesterol Lowering Biologic Drugs by Product
- 10.3 Middle East and Africa Cholesterol Lowering Biologic Drugs by End User
11 Company Profiles
- 11.1 Amgen
- 11.1.1 Amgen Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Amgen Cholesterol Lowering Biologic Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Amgen Cholesterol Lowering Biologic Drugs Products Offered
- 11.1.5 Amgen Recent Development
- 11.2 Regeneron Pharmaceuticals
- 11.2.1 Regeneron Pharmaceuticals Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Regeneron Pharmaceuticals Cholesterol Lowering Biologic Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Regeneron Pharmaceuticals Cholesterol Lowering Biologic Drugs Products Offered
- 11.2.5 Regeneron Pharmaceuticals Recent Development
- 11.3 Alnylam Pharmaceuticals
- 11.3.1 Alnylam Pharmaceuticals Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Alnylam Pharmaceuticals Cholesterol Lowering Biologic Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Alnylam Pharmaceuticals Cholesterol Lowering Biologic Drugs Products Offered
- 11.3.5 Alnylam Pharmaceuticals Recent Development
12 Future Forecast
- 12.1 Cholesterol Lowering Biologic Drugs Market Forecast by Regions
- 12.1.1 Global Cholesterol Lowering Biologic Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Cholesterol Lowering Biologic Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Cholesterol Lowering Biologic Drugs Market Forecast by Product
- 12.2.1 Global Cholesterol Lowering Biologic Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Cholesterol Lowering Biologic Drugs Revenue Forecast by Product 2019-2025
- 12.3 Cholesterol Lowering Biologic Drugs Market Forecast by End User
- 12.4 North America Cholesterol Lowering Biologic Drugs Forecast
- 12.5 Europe Cholesterol Lowering Biologic Drugs Forecast
- 12.6 Asia Pacific Cholesterol Lowering Biologic Drugs Forecast
- 12.7 Central & South America Cholesterol Lowering Biologic Drugs Forecast
- 12.8 Middle East and Africa Cholesterol Lowering Biologic Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Cholesterol Lowering Biologic Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Cholesterol Lowering Biologic Drugs . Industry analysis & Market Report on Cholesterol Lowering Biologic Drugs is a syndicated market report, published as Global Cholesterol Lowering Biologic Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Cholesterol Lowering Biologic Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
